Navigation Links
Michael J. Fox Foundation Awards $1 Million to Drive Critical New Research Tools and Technologies in Parkinson's Drug Development

NEW YORK, Feb. 9 /PRNewswire-USNewswire/ -- As part of its mission to do whatever it takes to speed development of life-transforming treatments and a cure for Parkinson's disease, The Michael J. Fox Foundation announced $1 million in total funding for seven research projects aiming to push forward critical research tools and new technologies to accelerate PD therapeutic development.

While new genetic and cellular targets have invigorated Parkinson's research over the past decade, converting these discoveries into practical treatments requires deliberate and strategic investment in the development of new research technologies and tools. This pursuit is critical to attaining the Foundation's ultimate goal: transformative new treatments that will make a tangible impact on patients' lives.

Five funded teams are working to develop improved pre-clinical disease models of PD that accurately mimic the pathology and symptoms of Parkinson's as it arises and progresses in humans. These models are critical not only for testing potential new Parkinson's treatments, but also for opening new therapeutic avenues to address particular clinical features of the disease.

Jim Greene, MD, PhD, of Emory University has been funded by MJFF since 2006 to develop an accurate model of gastrointestinal (GI) dysfunction, such as nausea, bloating and constipation, in Parkinson's. These symptoms of PD are poorly understood, and there is a dearth of treatment options to address them, in part because researchers lack a model that could be used to test new therapies. Dr. Greene is heading a collaboration between neurologists and GI specialists to examine the 'enteric nervous system' (ENS) -- a nervous system located in the stomach and intestines that contains, in both humans and pre-clinical models, nearly as many nerve cells as the brain. With follow-on funding from MJFF, the researchers are now building on Dr. Greene's exciting earlier results and examining the ENS in parkinsonian rodents to determine which nerve cells are damaged and thus responsible for causing the GI symptoms -- information that will dramatically speed efforts to develop therapeutic targets for new GI treatments.

Chenjian Li, PhD, of Weill Cornell Medical College was previously funded by MJFF to create the first rodent models of Parkinson's showing progressive degeneration of dopamine neurons, as is seen in the human condition. His team successfully used bacterial artificial chromosome (BAC) technology to generate rat lines with five of the most common genetic mutations associated with PD (three alpha-synuclein lines and two LRRK2 lines).  Now J. Timothy Greenamyre, MD, PhD, of the University of Pittsburgh is collaborating with Dr. Li to characterize the alpha-synuclein models' neurobehavioral deficits, neurochemical alterations, dopaminergic cell loss, neuropathology and molecular features. If successful, the project could lead, for the first time, to models of PD that faithfully recapitulate various components of the human disease and, optimally, help speed the development of new treatments.

The sixth funded team, led by Albert Leentjens, MD, PhD, of Maastricht University Hospital in the Netherlands, is working to validate clinical scales that would allow doctors to accurately measure anxiety disorders in PD. Dr. Leentjens will lead an international, six-center study assessing 360 Parkinson's patients for anxiety symptoms through a structured interview and completion of the most common anxiety rating scales. Information on disease variables, motor function, mood, and cognition will be collected. This is the largest study on anxiety disorders in Parkinson's disease to date, and will result in the first validated description of both established and atypical anxiety syndromes in PD as well as validation of the rating scales used to measure them -- a prerequisite for the design of effective clinical studies of anxiety in PD and new treatments to alleviate this troubling symptom.

The full list of funded projects, made possible through the generous support of The Brin Wojcicki Foundation, is below. As with all MJFF awards, continued funding is dependent on the achievement of specific, pre-determined milestones. Grant abstracts and researcher biosketches for all funded awards are available through the Searchable Database of Funded Grants on the Foundation's Web site,

Gastrointestinal Function in Parkinson's Rodents

James Greene, MD, PhD, Emory University

Analysis of the Role of PPN Neurons in Postural Disturbances in a Non-human Primate Model of Parkinson's Disease

Chantal Francois, PhD, Hopital de la Salpetriere

Characterization of E46K and A53T Alpha-Synuclein BAC Transgenic Rats

J. Timothy Greenamyre, MD, PhD, University of Pittsburgh

A Non-human Primate Alpha-Synuclein Model of Parkinson's Disease

Jeffrey Kordower, PhD, Rush University Medical Center

The Validation of Anxiety Scales in Parkinson's Disease

Albert Leentjens, MD, PhD, Maastricht University Hospital

Artificial Chromosome Transgenic Mice as Model for Progressive Parkinson's Disease

Robert Nussbaum, MD, University of California, San Francisco

The Michael J. Fox Foundation is dedicated to ensuring the development of better treatments, and ultimately a cure, for Parkinson's disease through an aggressively funded research agenda. MJFF has funded over $171 in research to date. 

SOURCE Michael J. Fox Foundation



SOURCE Michael J. Fox Foundation
Copyright©2010 PR Newswire.
All rights reserved

Related medicine news :

1. Would You Like to Own a Thriller Album Autographed by Michael Jackson Himself?
2. Aton Pharma Announces Michael H. Richardson to Head Orphan Drug Division
3. Michael J. Fox Foundation Awards $2.8 Million to Drive Development of Parkinsons Disease Biomarker Pipeline
4. Aleres Dr. Michael Taitel Presents Compelling Evidence at IBI/NBCH Health & Productivity Forum that Wellness Programs Positively Impact Health & Productivity
5. Michael Jackson Propofol Expert, Barry Friedberg MD, Spoke at Pan Pacific Surgery Meeting
6. TV Wellness Expert Jillian Michaels Teams With Harley-Davidson to Help Women Channel Their Inner Drive and Live More Fulfilling Lives
7. Michael J. Fox Foundation Awards $2 Million for Clinical Research on Postural Instability and Gait Disturbances in Parkinsons Disease
8. Michael J. Fox Foundation Awards $1 Million for Critical Step Toward Development of Dyskinesia Treatments
9. Rush Limbaugh & Michael Steele Join Tea Party Support & Social Security Institute-Demand GOP Senate Stop ObamaCare by Any Means Possible
10. Dr. Michael Aziz Releases a New Nutrition Book That Debunks Most Popular Diets and Diet Books
11. BIDMC scientists awarded grants from Michael J. Fox Foundation for Parkinsons research
Post Your Comments:
(Date:10/12/2015)... ... 2015 , ... The American Society of Clinical Hypnosis (ASCH) ... and clinical training in a health care discipline. , Many practitioners claim ... losing weight, managing pain, or stopping smoking, etc. Frequently, extravagant statements and guarantees ...
(Date:10/12/2015)... ... October 12, 2015 , ... AcousticSheep LLC, creators of ... in honor of Breast Cancer Awareness Month. During the month of October, ... a SleepPhones® Classic product to a breast cancer patient at the Cleveland Clinic. ...
(Date:10/12/2015)... ... October 12, 2015 , ... To help ... its charitable donation to the National Breast Cancer Foundation. The National Breast Cancer ... breast cancer through early detection, education, and support services. , The annual campaign ...
(Date:10/12/2015)... ... October 12, 2015 , ... NFL football fans who are interested in having an opportunity to ... CLICK HERE to donate to Smile for a Lifetime (S4L) Foundation and gift ... all-inclusive trip to the 2016 NFL Super Bowl! , Donors contributing $20.00 or more between ...
(Date:10/12/2015)... , ... October 12, 2015 , ... The translation for ... seamless migration of complete ARIS installations into the Microsoft world. The ARIS models ... As Microsoft Visio® is very familiar for both IT and Office users it is ...
Breaking Medicine News(10 mins):
(Date:10/12/2015)... October 12, 2015 ... to grow at 7.2% CAGR, microscopy market ... rising focus on nanotechnology, technological advancements, and ... report available with ... . --> Complete report on ...
(Date:10/12/2015)...   Royal Philips (NYSE: PHG, AEX: PHIA), ... a collaboration with Genomic Health , Inc. (NASDAQ: ... diagnostic tests, to leverage Philips digital pathology tools in ... testing processes.    --> ... samples and plays a crucial role in the diagnosis ...
(Date:10/12/2015)... , Oct. 12, 2015 Indivior PLC (LON: ... District of Delaware granted the Company,s ... Pharmaceuticals, Abbreviated New Drug Application (ANDA) No. 205299 to market ... (buprenorphine and naloxone) Sublingual Film (CIII) in the ... --> Since August 2013, Indivior has received Paragraph IV ...
Breaking Medicine Technology: